Related Experiment Video

Updated: May 25, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

Ryohei Katayama1, Alice T Shaw, Tahsin M Khan

  • 1Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA.

Science Translational Medicine
|January 27, 2012
PubMed

Insights

Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer patients often develop resistance to ALK tyrosine kinase inhibitors (TKIs). New ALK mutations, gene amplification, and other kinase activations drive resistance, necessitating tailored combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) shows high initial response rates to ALK tyrosine kinase inhibitors (TKIs).
  • Acquired resistance to ALK TKIs, particularly crizotinib, leads to disease relapse, typically within one year.
  • Understanding resistance mechanisms is crucial for developing effective, long-term treatment strategies.

Purpose of the Study:

  • To investigate the molecular mechanisms of acquired resistance to the ALK TKI crizotinib in NSCLC patients.
  • To identify novel ALK mutations, gene alterations, and co-occurring pathway activations contributing to drug resistance.
  • To evaluate the efficacy of next-generation ALK inhibitors against identified resistance mutations.

Main Methods:

  • Genomic analysis of tumor samples from 18 NSCLC patients with acquired resistance to crizotinib.
  • Next-generation sequencing to identify secondary mutations within the ALK tyrosine kinase domain.
  • Assessment of ALK gene amplification and activation of other signaling pathways (e.g., KIT, EGFR).
  • In vitro testing of next-generation ALK inhibitors against specific resistance mutations.

Main Results:

  • Secondary mutations in the ALK kinase domain, including novel resistance mutations, were identified in approximately 25% of patients.
  • ALK gene amplification was observed as a significant resistance mechanism.
  • Aberrant activation of other kinases, such as KIT amplification and epidermal growth factor receptor (EGFR) autophosphorylation, was detected.
  • Multiple resistance mechanisms were found to co-exist in some patients.
  • Next-generation ALK inhibitors demonstrated variable potency against different resistance mutations.

Conclusions:

  • Acquired resistance to crizotinib in ALK-positive NSCLC is driven by diverse genetic alterations within ALK and co-occurring pathway dysregulations.
  • The identification of specific resistance mechanisms is essential for predicting treatment response and guiding therapeutic decisions.
  • Combinatorial therapeutic strategies, tailored to individual resistance profiles, are warranted for patients relapsing on crizotinib.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...